Anti-MDA5-associated rapidly progressive-ILD—the intersection of hyperinflammation and fibrosis

The Lancet Rheumatology · Published 2026-05-01 · DOI 10.1016/s2665-9913(26)00079-2

Authors being retrieved — see the publisher record. https://doi.org/10.1016/s2665-9913(26)00079-2

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Redefining axial spondyloarthritis: more than just back pain · The Lancet Rheumatology · 2026 · Same journal
• Infection risk in adults with secondary HLH · The Lancet Rheumatology · 2026 · Same journal
• The at-risk-to-early continuum of enteropathic spondyloarthritis · The Lancet Rheumatology · 2026 · Same journal
• Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study · The Lancet Rheumatology · 2026 · Same journal
• Detection of GLP-1 and DPP-4 in synovial fluid: implications for therapeutical strategies in arthritis · The Lancet Rheumatology · 2026 · Same journal
• Prediction of psoriatic arthritis risk: watch for symptoms · The Lancet Rheumatology · 2026 · Same journal
• Lifestyle factors in difficult-to-treat rheumatoid arthritis · The Lancet Rheumatology · 2026 · Same journal
• Research in Brief · The Lancet Rheumatology · 2026 · Same journal
• Gout treat-to-target for whom? · The Lancet Rheumatology · 2026 · Same journal
• Announcing The Lancet Rheumatology commission on reproductive health and family planning in immune-mediated long-term conditions: empowering special reproductive journeys · The Lancet Rheumatology · 2026 · Same journal